Our Experts

Name: He Zhenyu
Title: chief physician
Email: hezhy@sysucc.org.cn

Dr. He Zhenyu has been working at Sun Yat-sen University Cancer Center since July 2001 after completing his undergraduate program of clinical medicine at Sun Yat-sen University of Medical Sciences. He obtained a master's degree in June 2007, and visited the National Cancer Centre Singapore as a visiting scholar from August 2013 to July 2014. He currently serves as an attending professor. His specialty is thoracoabdominal Radiation Oncology at Sun Yat-sen University Cancer Center, specializing in clinical work and scientific research in radiotherapy and combination therapy for breast cancer. He has taken charge of theory teaching and clinical teaching for physicians studying further from various regions, and for years and has participated in the instruction for common cases and consultations for difficult cases in associate organizations at all levels. The project of Pretreatment of Hematopoietic Stem Cell Transplantation: Improvement of Total Body Irradiation in which he assisted was awarded the third prize of Guangdong Provincial Department of Science and Technology in 2005. He has also led and participated in many multi-centric clinical studies at home and abroad, and published more than 10 SCI papers as lead author or corresponding author in the last 3 years.


[1] Guo SP, Wu SG, Zhou J, Feng HX, Li FY, Wu YJ, Sun JY, He ZY*. Transdermal fentanyl for pain due to chemoradiotherapy -induced oral mucositis in nasopharyngeal cancer patients: Evaluating efficacy, safety, and improvement in QOL. Drug Des Devel Ther.2014 May 12;8:497-503 (*corresponding author)[2] He ZY, Wu SG, Zhou J, Sun JY, Li FY, Lin Q, Guo L, Lin HX. Benefit of post-mastectomy radiotherapy at the supra-/infraclavicular lymphatic drainage area in breast cancer patient .Asian Pac J Cancer Prev. 2014;15(14):5557-63. (*corresponding author)[3] Wu SG, Zhou J, Ren Y, Sun J, Li F, Lin Q, Lin H, He Z*. Tumor location is a prognostic factor for survival of Chinese women with T1-2N0M0 breast cancer. Int J Surg.2014;12(5):394-8 (*corresponding author)[4] Wu SG, He ZY #, Zhou J, Sun JY, Li FY, Lin Q, Guo L, Lin HX. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast. 23(1),88-93,2014 (# co-lead author)[5] Wu S, He Z#, Guo J, Li F, Lin Q, Guan X. Dosimetric Comparison of Normal Structures Associated with Accelerated Partial Breast Irradiation and Whole Breast Irradiation Delivered by Intensity Modulated Radiotherapy for Early Breast Cancer after Breast Conserving Surgery. Clin Transl Oncol. 2014 Jan; 16(1):69-76 (# co-lead author)[6] Wu SG, Sun JY, Zhou J, Li FY, Lin Q, Lin HX, He ZY* .The value of radiotherapy in breast cancer patients with isolated ipsilateral supraclavicular lymph node metastasis without distant metastases at diagnosis: a retrospective analysis of Chinese patients. Onco Targets Ther. 2014 Feb 15;7:281-8. (*corresponding author)[7] Li FY, Wu SG, Zhou J, Sun JY, Lin Q, Lin HX, Guan XX, He ZY* .Prognostic Value of Ki-67 in Breast Cancer Patients with Positive Axillary Lymph Nodes: A Retrospective Cohort Study. PLoS One. 9(2),e87264. 2014 (*corresponding author)[8] Wu S, Li Q, Zhu Y, Sun J, Li F, Lin H, Guan X, He Z*. Role of goserelin in combination with endocrine therapy for the treatment of advanced breast cancer in premenopausal women positive for hormone receptor: a retrospective matched case-control study. Cancer Biother Radiopharm. 28(10),697-702,2013. (*corresponding author)[9] He Z, Wu S, Li Q, Lin Q, Xu J. Use of the Metastatic Lymph Node Ratio to Evaluate the Prognosis of Esophageal Cancer Patients with Node Metastasis Following Radical Esophagectomy. PLoS One. 8(9),e73446,2013.[10] Sun JY, Wu SG, Li S, Li FY, Chen WF, Lin Q, He ZY*. Locoregional recurrence of pT3N0M0 breast cancer after mastectomy is not higher than that of pT1-2N0M0: an analysis for radiotherapy. Cancer Sci. 104(5),599-603,2013. (*corresponding author)[11] Wu SG, Chen Y, Sun JY, Li FY, Lin Q, Lin HX, He ZY*. Using the lymph nodal ratio to predict the risk of locoregional recurrence in lymph node-positive breast cancer patients treated with mastectomy without radiation therapy. Radiat Oncol. 8(1),119, 2013. (*corresponding author) [12] Wu SG, He ZY #, Li Q, Sun JY, Li FY, Lin Q, Lin HX, Guan XX. Prognostic value of metastatic axillary lymph node ratio for chinese breast cancer patients. PLoS One. 8(4),e61410,2013. (# co-lead author)[13] Wu SG, He ZY*, Li Q, Li FY, Lin Q, Lin HX, Guan XX. Predictive value of breast cancer molecular subtypes in Chinese patients with four or more positive nodes after postmastectomy radiotherapy. The Breast. 21(5),657-61, 2012. (*corresponding author)[14] He ZY, Tong Q, Wu SG, Li FY, Lin HX, Guan XX.A comparison of quality of life of early breast cancer patients treated with accelerated partial breast irradiation versus whole breast irradiation in China. Breast Cancer Res Treat. 133(2),545-52,2012.[15] He ZY, Tong Q, Wu SG, Li FY, Lin HX, GuanXX. A Comparison of Quality of Life and Satisfaction of Women with Early Stage Breast Cancer Treated with Breast Conserving Therapy vs. Mastectomy in Southern China. Support Care Cancer. 20(10),2441-9,2012.


Last Updated on: August 2014 by International Office, Sun Yat-sen University Cancer Center


Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.